Clinical Trial Update: REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) [Phase 3]

View source ↗

Summary

Phase 3 REVEAL 2 trial evaluating VGX-3100 delivered by electroporation for cervical HSIL completed, with results posted on 2024-10-17.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Dysplasia
• Cervical Intraepithelial Neoplasia

Drugs mentioned

• VGX-3100

Snippet

Sponsor: Inovio Pharmaceuticals | Conditions: Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion | Phase 3 | Status: COMPLETED | Results posted: 2024-10-17